REYKJAVIK, Iceland, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to its global business development and commercial operations team. Anil Okay, Chief Commercial Officer, is stepping down to serve as Chief Executive Officer of Adalvo. Trisha Durant has joined Alvotech as Senior Vice President, Global Business Development and Commercial Operation, ex-Nor ...

Company Overview - Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [5] - The company aims to be a leader in the biosimilar space by delivering high-quality, cost-effective products and services through a fully integrated approach [5] - Alvotech has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), marketed in multiple global markets [5] - The current development pipeline includes nine disclosed biosimilar candidates targeting various conditions such as autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer [5] Recent Developments - Patrik Ling has joined Alvotech as VP Investor Relations Scandinavia, based in Stockholm [1] - Ling has over 25 years of experience in the life-science industry, previously serving as a Senior Equity Analyst at DNB Carnegie [2] - His expertise in both pharmaceuticals and finance is expected to enhance Alvotech's efforts to broaden its shareholder base in Scandinavia [3] Strategic Focus - Alvotech is expanding its portfolio of products and has established a new base of R&D operations in Sweden [4] - The company emphasizes the importance of biosimilars in meeting the growing demand for high-quality biologics and controlling healthcare costs [4] - Alvotech has formed strategic commercial partnerships to enhance its global reach and leverage local expertise across various markets, including the US, Europe, Japan, China, and parts of South America, Africa, and the Middle East [5]

Core Insights - Alvotech has appointed Linda Jónsdóttir as the new Chief Financial Officer (CFO), bringing extensive experience in finance and corporate leadership from various industries [1][3][2] - Joel Morales, the previous CFO since 2020, will step down to focus on family but will remain in an advisory role to ensure a smooth transition [1][4] Company Overview - Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines, aiming to be a leader in the biosimilar space with high-quality, cost-effective products [5] - The company has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), and a pipeline of nine disclosed biosimilar candidates targeting various diseases [5] - Alvotech has established strategic commercial partnerships across multiple regions, including the United States, Europe, Japan, and parts of South America, Africa, and the Middle East [5][7]

Group 1: Company Overview - Alvotech is a biotech company focused on the development and manufacture of biosimilar medicines for patients worldwide [3] - The company aims to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services [3] - Alvotech has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), marketed in multiple global markets [3] - The current development pipeline includes nine disclosed biosimilar candidates targeting various diseases, including autoimmune disorders and cancer [3] Group 2: Strategic Partnerships - Alvotech has formed a network of strategic commercial partnerships to enhance its global reach and leverage local expertise [3] - Key commercial partners include Teva Pharmaceuticals, STADA Arzneimittel AG, and Fuji Pharma Co., Ltd., among others, covering various territories [3] - Each partnership is tailored to specific products and regions, enhancing Alvotech's market presence [3] Group 3: Liquidity Provider Agreement - Alvotech has entered into an agreement with DNB Carnegie Investment Bank AB for liquidity provider services for its Swedish Depository Receipts (SDRs) [1] - DNB Carnegie will continuously quote prices for Alvotech's SDRs to ensure liquidity and reduce the spread between buying and selling prices [2] - The liquidity provider arrangement is set to commence on May 20, 2025 [2]

Core Viewpoint - Alvotech is set to release its financial results for Q1 2025 on May 7, 2025, and will hold a conference call on May 8, 2025, to discuss these results and recent business highlights [1]. Company Overview - Alvotech is a biotech company focused on developing and manufacturing biosimilar medicines globally, aiming to be a leader in the biosimilar market by providing high-quality, cost-effective products [3]. - The company has two approved biosimilars, Humira® (adalimumab) and Stelara® (ustekinumab), which are marketed in multiple global markets [3]. - Alvotech's development pipeline includes nine disclosed biosimilar candidates targeting various conditions such as autoimmune disorders, eye disorders, osteoporosis, respiratory diseases, and cancer [3]. - The company has established a network of strategic commercial partnerships across the United States, Europe, Japan, China, and other regions, enhancing its global reach [3]. Investor Relations - Information regarding the webcast and conference call participation is available on Alvotech's investor website, with the webcast being archived for 90 days post-event [2]. - The company encourages engagement through its investor portal and social media platforms [4].